Meloxicam–rizatriptan

A combination tablet of the triptan rizatriptan and the NSAID meloxicam, FDA-approved for acute treatment of migraine with or without aura in adults.

psilodex.org/m/meloxicam-rizatriptan · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: ~18 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Meloxicam–rizatriptan”, v2026.10.05. psilodex.org/m/meloxicam-rizatriptan

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Migraine attacks (acute treatment)

Sources [1]

Other safety

Boxed warning: the NSAID component (meloxicam) increases the risk of serious cardiovascular thrombotic events, including heart attack and stroke, and of serious gastrointestinal bleeding, ulceration and perforation, which can be fatal.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

Not studied with psilocybin; both parts can raise blood pressure and one acts on serotonin, so added effects are possible.

Detail This product combines rizatriptan, a triptan that narrows blood vessels, with the NSAID (anti-inflammatory) meloxicam. Its label reports serotonin syndrome with SSRIs, SNRIs, TCAs and MAO inhibitors. The label also reports new or worsened high blood pressure from the NSAID. The enzyme MAO-A mainly breaks down rizatriptan, and it also broke down psilocin in lab studies. There are no psilocybin data. In theory, it adds to psilocybin's serotonergic (serotonin-boosting) effects and brief blood pressure rise. Sources [1][2]

Human data with psilocybin: No psilocybin data; based on how it works and its label
Half-life: ~18 h (meloxicam); ~2 h (rizatriptan) (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

3 listed · counted on reports

Liver injury: The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

SYMBRAVO (meloxicam and rizatriptan) tablet · FDA label (DailyMed) — revised 2025-11 | Serotonergic: 5.18 Serotonin Syndrome "Serotonin syndrome may occur with triptans, including SYMBRAVO particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and MAO inhibitors (MAOIs)" | Raises blood pressure or heart rate: 5.9 Hypertension/Increase in Blood Pressure "NSAIDs, including meloxicam, a component of SYMBRAVO, can lead to new onset of hypertension or worsening of pre-existing hypertension" | Liver injury: 5.8 Hepatotoxicity "rare, sometimes fatal, cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported" | 7 Drug Interactions "Rizatriptan is principally metabolized via monoamine oxidase, ‘A’ subtype (MAO-A)." | BOXED WARNING "Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal." | 12.3 Pharmacokinetics "After administration of SYMBRAVO, mean elimination half-life is approximately 18 hours for meloxicam and 2 hours for rizatriptan."
Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689. — Lab studies: MAO-A, CYP2D6 and CYP3A4 metabolized psilocin; glucuronidation and conversion to 4-HIAA are the main routes.

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →